Renal cell carcinoma (RCC) is the most common type of kidney cancer and comprises
several subtypes with unique characteristics. The most common subtype (~ 70% of cases) is …

Advances in cancer immunity have promoted a major breakthrough in the field of cancer
therapy. This is mainly associated with the successful development of immune checkpoint …

Kidney cancer has unique features that make this malignancy attractive for therapeutic
approaches that target components of the immune system. Immune checkpoint inhibition is a …

Over the past decade, the treatment landscape for patients with metastatic renal cell
carcinoma (RCC) has evolved dramatically. The therapeutic options available have …

The approval of immunotherapeutic agents and immunotherapy-based combination
strategies in recent years has revolutionized the treatment of patients with advanced renal …

Background The phase 3 CheckMate 214 trial demonstrated higher response rates and
improved overall survival with nivolumab plus ipilimumab versus sunitinib in first-line …

The treatment landscape of metastatic renal cell carcinoma (mRCC) has been transformed
with the advent of antiangiogenics, notably tyrosine kinase inhibitors (TKIs) targeting …

Simple Summary Renal cell carcinoma is particularly characterized by its high
vascularization and dense immune cells infiltration. The angiogenesis blockade in …

Background Sarcomatoid renal cell carcinoma (sRCC) represents a rare form of renal cell
carcinoma marked by an aggressive biology, poor prognosis and little benefit from anti …

Simple Summary In recent years, the therapeutic armamentarium of mccRCC has changed
dramatically with the emergence of targeted therapy and immune checkpoint inhibitors, used …